Linaclotide Research: What 552 Studies Show (2026) | RetatrutideCompare

Linaclotide — 552 studies indexed on PubMed. Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen. Half-life: Negligible systemic absorption. FDA status: FDA-approved (2012).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Linaclotide?

There are approximately 552 studies indexed on PubMed that mention Linaclotide (Linzess, Constella), based on a search last updated 2026-06-18.

Is Linaclotide FDA-approved?

FDA status: FDA-approved (2012).

How does Linaclotide work?

Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.

Reference facts

Also known as: Linzess, Constella
Category: Gastrointestinal
Mechanism of action: Guanylate cyclase-C agonist on intestinal epithelium; elevates intracellular cGMP, opening CFTR and increasing chloride / fluid secretion into the gut lumen.
Targets: GC-C receptor
Indications under research or approved: Chronic idiopathic constipation, IBS-C, Functional constipation in pediatrics
Regulatory status (reference entry): FDA-approved (2012)
Half-life: Negligible systemic absorption
Sequence: CCEYCCNPACTGCY
Sequence notes: 14-residue cyclic peptide with three disulfide bonds; oral, gut-restricted.
Molecular weight (Da): 1527
Originator / sponsor: Ironwood / AbbVie
First reported: 2008

Primary References

Linzess FDA label

Explore research articles about Linaclotide

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.